Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.

Conclusion: Denosumab significantly increased L-BMD and H-BMD to comparable degrees in both groups; therefore, it represents a good therapeutic option for OP receiving breast cancer treatment as well as primary OP. Also, vitamin D supplementation is required due to the potential hypocalcemia, and estrogen may be responsible for the decrease of serum calcium in the breast cancer patients.
PMID: 29559791 [PubMed]

Source: Clinical Genitourinary Cancer - March 22, 2018 Category: Cancer & Oncology Authors: Nakamura Y, Kamimura M, Morikawa A, Taguchi A, Suzuki T, Kato H Tags: Ther Clin Risk Manag Source Type: research